- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04977869
Safety and Efficacy Study of Remote Ischemic Conditioning Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation
February 26, 2024 updated by: Yi Yang
Safety and Efficacy Study of Remote Ischemic Conditioning Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation: A Multicenter, Randomized, Parallel-controlled Clinical Trial
The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
In this study, 498 cases of ischemic stroke who undergo endovascular thrombectomy within 24 hours from the onset are included in 10 centers in China according to the principle of random, and parallel control.
The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days.
The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day for 7 consecutive days.
Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.
Study Type
Interventional
Enrollment (Estimated)
498
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yi Yang, MD, PhD
- Phone Number: 0086-13756661217
- Email: doctor_yangyi@163.com
Study Contact Backup
- Name: Zhenni Guo, MD, PhD
- Email: zhen1ni2@163.com
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130000
- Recruiting
- The First Hospital of Jilin University
-
Contact:
- Yi Yang, MD, PhD
- Email: doctor_yangyi@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 1) Age ≥ 18 years, male or female
- 2) Diagnosis of acute ischemic stroke due to large vessel occlusion of anterior circulation (large artery occlusion confirmed by head CTA or DSA) and history of emergent endovascular thrombectomy
- 3) Baseline NIHSS ≥ 6
- 4) Premorbid mRS ≤ 2
- 5) Written informed consent obtained from the patient or legally responsible person
Exclusion Criteria:
- 1) Contraindication of endovascular thrombectomy
- 2) Contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, and subclavian steal syndrome
- 3) Head CT showing cerebral hernia and midline displacement
- 4) Pregnancy or lactation
- 5) Previous remote ischemic conditioning therapy or similar treatment
- 6) Severe hepatic and renal dysfunction
- 7) Life expectancy of less than 3 months or inability to complete the study for other reasons
- 8) Unwilling to be followed up or poor compliance
- 9) Current or past participation in other clinical research, or participation in this study within 3 months prior to admission
- 10) Other conditions that the researchers think make the patient unsuitable for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: RIC+Standard medical treatment
RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion.
Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
RIC will be conducted twice daily for 7 days after endovascular thrombectomy.
Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.
|
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion.
Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
|
Placebo Comparator: Sham RIC+Standard medical treatment
Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion.
Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
RIC will be conducted twice daily for 7 days after endovascular thrombectomy.
Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.
|
Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion.
Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with modified Rankin Scale (mRS) Score 0-2
Time Frame: 3 months
|
Proportion of patients with modified Rankin Scale (mRS) Score 0-2.
Ranged from 0 to 6, a low value represents a better outcome.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of adverse events during follow-up
Time Frame: 90 days
|
Severe adverse events through day-90 after the onset of acute ischemic stroke.
|
90 days
|
Frequency of Hemorrhagic transformation during hospitalization
Time Frame: 7 days
|
Frequency of Hemorrhagic transformation during hospitalization
|
7 days
|
National Institute of Health stroke scale (NIHSS) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
Time Frame: 24 hours, 7 days, 30±3 days, 90±3 days
|
National Institute of Health stroke scale (NIHSS) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
Ranged from 0 to 42, a low value represents a better outcome.
|
24 hours, 7 days, 30±3 days, 90±3 days
|
Barthel Index (BI) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
Time Frame: 24 hours, 7 days, 30±3 days, 90±3 days
|
Barthel Index (BI) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
Ranged from 0 to 100, a high value represents a better outcome.
|
24 hours, 7 days, 30±3 days, 90±3 days
|
modified Rankin Scale (mRS) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
Time Frame: 24 hours, 7 days, 30±3 days, 90±3 days
|
modified Rankin Scale (mRS) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
Ranged from 0 to 6, a low value represents a better outcome.
|
24 hours, 7 days, 30±3 days, 90±3 days
|
The expanded Thrombolysis In Cerebral Infarction (eTICI) scale immediately after EVT
Time Frame: immediately after EVT
|
eTICI grade 0 is equivalent to no reperfusion or 0% filling of the downstream territory; eTICI 1 reflects thrombus reduction without any reperfusion of distal arteries; eTICI 2a is reperfusion in less than half or 1-49% of the territory; eTICI 2b50 is 50-66% reperfusion, exceeding the modified TICI (mTICI) 2B threshold but below the original TICI 2B cut-off point; eTICI 2b67 is 67-89% reperfusion, exceeding TICI but below TICI 2C; eTICI 2c is equivalent to TICI 2C or 90-99% reperfusion; and eTICI 3 is complete or 100% reperfusion, tantamount to TICI 3.
|
immediately after EVT
|
Vascular recanalization rate 24 hours after EVT
Time Frame: 24 hours,
|
Vascular recanalization rate 24 hours after EVT
|
24 hours,
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of early withdrawal for safety or tolerability reasons
Time Frame: 7 days
|
The number of early withdrawal for safety or tolerability reasons
|
7 days
|
Numeric rating scales (NRS) score during intervention
Time Frame: 7 days
|
Numeric rating scales (NRS) score during intervention.
Ranged from 0 to 10, a low value represents a less pain.
|
7 days
|
Blood pressure at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
Time Frame: 24 hours, 7 days, 30±3 days, 90±3 days
|
Blood pressure at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
|
24 hours, 7 days, 30±3 days, 90±3 days
|
Heart rate at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
Time Frame: 24 hours, 7 days, 30±3 days, 90±3 days
|
Heart rate at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.
|
24 hours, 7 days, 30±3 days, 90±3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2021
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
July 13, 2021
First Submitted That Met QC Criteria
July 26, 2021
First Posted (Actual)
July 27, 2021
Study Record Updates
Last Update Posted (Estimated)
February 28, 2024
Last Update Submitted That Met QC Criteria
February 26, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SERIC-EVT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
Clinical Trials on Remote ischemic conditioning
-
Yi YangRecruiting
-
University of ArizonaRecruitingBrain Injuries | Brain Injuries, Traumatic | Traumatic Brain Injury | Brain TraumaUnited States
-
Grethe AndersenCompletedCerebrovascular Disorders | Central Nervous System Diseases | Ischemic Stroke | Stroke, AcuteDenmark
-
Rutgers, The State University of New JerseyUnknownLiver Diseases | Urologic Diseases | Pancreatic Diseases | Complication of Surgical Procedure | Laparotomy | Laparoscopy | Gastrointestinal Disease | Retroperitoneal Disease | Pelvis DiseaseUnited States
-
Capital Medical UniversityUnknown
-
Capital Medical UniversityUnknownAneurysm, Ruptured | Coiling TherapyChina
-
University of AarhusNovo Nordisk A/S; Aarhus University Hospital; University Medical Center Groningen and other collaboratorsUnknownKidney Transplantation | Acute Kidney Injury | Glomerular Filtration Rate | Delayed Graft FunctionNetherlands, Denmark, Sweden
-
Capital Medical UniversityRecruiting
-
Yi YangRecruitingAcute Ischemic StrokeChina
-
Yi YangRecruitingEssential HypertensionChina